By taking advantage of this property, Raffin et al. developed a CAR directed against citrullinated vimentin (CV), a posttranslational modified intermediate filament protein exclusively and abundantly present in the extracellular matrix of the synovial tissue of 50% of patients with rheumatoid arthritis (RA), aiming to restore homeostasis at the site of inflammation [65]. This evidence concerns the gene VIM and rheumatoid arthritis.